TFF3 and gastroesophageal reflux disease: Using the results of the BEST3 trial, we conducted a cost-utility analysis of offering Cytosponge-TFF3 testing for patients on long-term treatment with acid suppressants for gastro-esophageal reflux disease (GERD) compared with the current standard of care.